Sudarshan Pharma to Acquire 76% Stake in Target Company

Sudarshan Pharma Industries Ltd has entered into a Memorandum of Understanding (MoU) to acquire 1,24,64,000 equity shares, representing 76% of the paid-up equity share capital, of a target company. The acquisition includes the target's business, manufacturing plant, and team, subject to due diligence and regulatory approvals. This move aims to achieve backward integration and establish end-to-end manufacturing capabilities for Sudarshan Pharma. The consideration involves cash and 40 lakh shares from Sudarshan Pharma's promoters. The target entity possesses accreditations from US FDA, WHO Geneva, and others, and has projected revenues for FY25-26. Upon completion, the target company will become a subsidiary of Sudarshan Pharma Industries Limited. The acquisition is expected to be completed by October 10, 2026.